Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Operations (2016 - 2021)

Historic Cash from Operations for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $4.2 million.

  • Neurocrine Biosciences' Cash from Operations fell 9555.56% to $4.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $256.5 million, marking a year-over-year increase of 1225.38%. This contributed to the annual value of $595.4 million for FY2024, which is 5270.58% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Cash from Operations stood at $4.2 million for Q4 2021, which was down 9555.56% from $61.8 million recorded in Q3 2021.
  • In the past 5 years, Neurocrine Biosciences' Cash from Operations ranged from a high of $118.9 million in Q2 2020 and a low of -$112.5 million during Q1 2019
  • For the 5-year period, Neurocrine Biosciences' Cash from Operations averaged around $32.0 million, with its median value being $45.5 million (2017).
  • Per our database at Business Quant, Neurocrine Biosciences' Cash from Operations crashed by 23651.2% in 2017 and then skyrocketed by 84024.7% in 2018.
  • Neurocrine Biosciences' Cash from Operations (Quarter) stood at $40.6 million in 2017, then grew by 24.44% to $50.5 million in 2018, then surged by 93.11% to $97.5 million in 2019, then dropped by 3.08% to $94.5 million in 2020, then plummeted by 95.56% to $4.2 million in 2021.
  • Its Cash from Operations stands at $4.2 million for Q4 2021, versus $61.8 million for Q3 2021 and $103.2 million for Q2 2021.